A Phase 1b2a Randomized, Double-blind Study to Evaluate Safety and Effects of JMT202 Injection in Chinese Adults With Hypertriglyceridemia

What this Trial Is About

Researchers are evaluating the safety and tolerability of multiple subcutaneous injections of JMT202 in Chinese adults with hypertriglyceridemia. This study is a Phase 1b2a randomized, double-blind, placebo-controlled trial aimed at assessing how participants respond to this investigational treatment, including its effects on triglyceride levels and overall health markers. Participants will receive either JMT202 injections or placebo injections according to the study protocol. The study involves multiple doses administered under medical supervision. Some participants in each dose group will also undergo MRI-PDFF scans to assess fat content. Throughout the trial, participants are expected to maintain their usual diet and exercise habits while avoiding alcohol and strenuous exercise before visits. During the study, participants will undergo regular safety assessments including monitoring for treatment-emergent adverse events, vital signs, physical exams, laboratory tests, electrocardiograms, and injection site reactions from Day 1 to Day 99. The trial period includes careful observation of health changes and adherence to stable lipid-lowering treatments. The total duration of participant involvement spans from screening through approximately three months of follow-up after treatment begins.

a Phase 1b/2a Study of JMT202 Injection in Participants With Hypertriglyceridemia